1YBelow half the group
Rank 33 of 63 funds
Return +19.93%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 33No. 1 is SCBGENOME(E) +68.99%
SCB GLOBAL HEALTH CARE EQUITY FUND
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
SCBGHC invests through the master fund Janus Henderson Global Life Sciences Fund 101.16%
This fundSCBGHC
The fund that actually investsJanus Henderson Global Life Sciences FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.72%
Johnson & Johnson JNJ7.87%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it trailed half its group; over 5 years it returned +3.22% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +68.99%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +10.16% | +2.40% | +2.51% | +7.26% | +5.11% | +13.95% | +19.93% | +41.95% | +17.16% | +66.12% | +129.54% |
Largest drawdown in the selected period −28.28% Previous peak 12 Feb 2020 (NAV 7.4022) → Trough 23 Mar 2020 (NAV 5.3085) · Back to the previous peak on 3 Jul 2020, after 3 months
Currently −2.57% from the peak NAV of 11.1508 (19 Aug 2026)
Over 5 years, SCBGHC returned 0.19 per unit of volatility, ranking 7 of 33 funds · The highest is FP HCARE-A (0.44)
Paid 2 times in the past 12 months, totalling 2.7000 THB per unit, or 24.85% of NAV
SCBGHC pays cash dividends to unitholders from part of the fund's profit. Below is a summary of when you get paid, how much, and how regularly
You must buy and hold units before the book close to receive that round's dividend
The last 4 dividends Sep 24 0.3800 THB · Sep 25 0.1700 THB · Mar 26 1.7500 THB · Sep 26 0.9500 THB, and the next round is about 0.8125 THB on 11 Mar 2027Paid on schedule 3 times in a row, so the next round is estimated from this pattern · This is not an AMC announcement. The actual date and amount may differ, or no dividend may be paid
THB/unit, totalled by year of payment · * 2026 to 3 Nov 2026
Based on NAV 11.5768 → 10.8644 THB (3 Nov 2025 – 3 Nov 2026) and dividends over the same period · Paid more than the fund earned this year. The difference came from earlier accumulated profits or capital
Unitholders' total value doesn't disappear. Part of it moves from the NAV into cash (the example assumes asset prices don't change that day) · See the D markers on the NAV chart
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว (Feeder Fund) ได้แก่ Janus Henderson Global Life Sciences Fund (กองทุนหลัก) ชนิดหน่วยลงทุน (share class) I acc สกุลเงินดอลลาร์สหรัฐ (USD) กองทุนหลักบริหารโดย Henderson Management S.A.จดทะเบียนภายใต้กฎหมายของประเทศไอร์แลนด… Its largest holdings are หน่วยลงทุน JANUS HENDERSON GLOBAL LIFE SCIENCES FUND 100.51% (fact sheet 31 Aug 2026)
Risk level 7 of 8 (High risk). Since 2 Sep 2015, its NAV has fallen as much as −28.28% from its peak.
Actual total expense ratio (TER) 1.72% a year, against a ceiling of 2.90%. Management fee 1.61%. Front-end fee 1.61%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
Yes. The latest was 0.9500 THB per unit, book close 11 Sep 2026, paid 24 Sep 2026 · 15 payments so far, totalling 5.3107 THB per unit. Dividends are subject to 10% withholding tax and are not guaranteed
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
Almost fully hedged. As of 31 Aug 2026, 100.09% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · SCBGHC: pays dividends, TER 1.72% · SCBGHCA: no dividends, TER 1.72% · SCBGHCE: see the conditions in the prospectus · SCBGHCP: see the conditions in the prospectus · SCBGHCR: see the conditions in the prospectus
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Unitedhealth Group UNH4.32%
AstraZeneca AZN.L3.75%
Thermo Fisher TMO3.39%
Novartis NOVN2.76%
Roche ROG2.71%
argenx ARGX2.48%
Merck & MRK2.38%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
ABBVIE ABBVHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Merck & MRKHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (101.16% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +22.37% per year
No. 1 is FP HCARE-A +6.71% per year
| +74.79% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.1 | +1.8 | −6.3 | +1.3 | +1.8 | +8.1 | −0.9 | +3.3 | −4.4 | +6.4 | −0.5 | · | +10.2* |
| 2025 | +5.2 | −0.4 | −4.8 | −0.9 | −5.9 | +1.7 | −1.2 | +5.5 | +2.2 | +8.3 | +8.9 | −0.5 | +18.3 |
| 2024 | +2.1 | +3.5 | +1.5 | −5.1 | +3.1 | +2.8 | +1.9 | +4.1 | −3.0 | −3.2 | −0.8 | −7.9 | −1.9 |
| 2023 | −0.2 | −4.2 | +1.8 | +3.5 | −2.8 | +2.8 | +0.3 | −1.8 | −4.2 | −7.0 | +6.7 | +7.0 | +0.9 |
| 2022 | −9.3 | +0.3 | +3.4 | −6.8 | −1.2 | −0.8 | +4.2 | −3.5 | −3.2 | +8.2 | +4.9 | −1.4 | −6.3 |
THB/unit by book-close date
0 of 15 book-close dates match the SEC dividend history · The rest are inferred from the dates NAV fell by the dividend amount